Antimicrobial resistance (AMR) is the result of a natural process whereby infectious agents develop resistance to the drugs we use to treat them. This process is accelerated by overuse and misuse of those drugs in humans, animals and the environment.
Countless efforts have been made to describe the many different facets of antibiotic resistance and the interventions needed to meet the challenge. However, coordinated action is largely absent, especially at the political level, both nationally and internationally.
AMR provides a unique opportunity for policy makers to adopt a demonstration project for the Circular Health Initiative. Linking AMR and viral pandemics, the wider field of infectious diseases and global health, in addition to climate change challenges and a holistic approach to resilience and sustainable development, provides real opportunities for interconnectedness to be a data driven endeavor rather than an abstract idea.
The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. GARDP works with partners to ensure sustainable access to treatments, promoting responsible use and affordability to all in need.
Promoting a Rational One-Health Approach to Antibiotic Crisis Through an European Training Network
We are collaborating with the University of Oslo, Department of Pharmacy, to create a new European Training Network of pharmacists through interdisciplinary and transversal methodologies.